熱門資訊> 正文

Adagio Medical宣布发布美国早期可行性研究的结果，评估超低温心脏消融治疗疤痕相关室性心动过速

2026-02-04 21:10

Adagio Medical Holdings, Inc(ADGM) 0

Results demonstrated a favorable safety profile, with no device- or procedure-related major adverse events measured at both seven and 30 days, and strong acute and chronic performance. Among 14 patients with inducible VT tested both before and after ablation, 92.9% achieved non-inducibility of targeted clinical VT. At a mean follow-up of 24 weeks, antiarrhythmic drugs were either completely discontinued or reduced in 72% of the patients, and 83.3% of the patients were free from implantable cardioverter-defibrillator (ICD) shock, with a notable reduction in the overall VT burden.
Adagio's proprietary ULTC technology utilizes near-critical nitrogen to achieve temperatures approaching –196°C, enabling the creation of deeper and potentially transmural lesions compared with other existing ablation modalities. This study represents the first published U.S. clinical experience for ULTC under the FDA's EFS framework.
"The publication of this study marks an important milestone for Adagio Medical and for patients with complex ventricular arrhythmias," said Todd Usen, Chief Executive Officer of Adagio Medical. "These results highlight the potential of ultralow temperature ablation to address a significant unmet need in VT treatment and underscores the value of the FDA's Early Feasibility Study program in accelerating patient access to innovative technologies. We look forward to sharing the results of our FULCRUM-VT pivotal trial at the Heart Rhythm Society scientific meeting in April.
Patients enrolled in the EFS will be included in the safety analyses of Adagio Medical's FULCRUM-VT pivotal Investigational Device Exemption (IDE) study. FULCRUM-VT, which completed enrollment in October 2025, is designed to support U.S. regulatory approval of Adagio's vCLASTM Cryoablation System, which is expected by year end 2026,

Adagio Medical宣布发布美国早期可行性研究的结果，评估超低温心脏消融治疗疤痕相关室性心动过速

推薦文章

美股機會日報 | 凌晨3點！美聯儲將公佈1月貨幣政策會議紀要，納指期貨漲近0.5%；13F大曝光！巴菲特連續三季減持蘋果

美股機會日報 | 阿里發佈千問3.5！性能媲美Gemini 3；馬斯克稱Cybercab將於4月開始生產

港股周報 | 中國大模型「春節檔」打響！智譜周漲超138%；鉅虧超230億！美團周內重挫超10%

一周財經日曆 | 港美股迎「春節+總統日」雙假期！萬億零售巨頭沃爾瑪將發財報

從軟件到房地產，美國多板塊陷入AI恐慌拋售潮

Meta計劃為智能眼鏡添加人臉識別技術

危機四伏，市場卻似乎毫不在意

財報前瞻 | 英偉達Q4財報放榜在即！高盛、瑞銀預計將大超預期，兩大關鍵催化將帶來意外驚喜？